WASHINGTON – PET with 89Zr-IAB22M2C provides detailed information on CD8 T-cell biodistribution in patients with advanced solid tumors...
WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
WASHINGTON – Targeted next-generation sequencing may help identify SCLC patients likely to benefit from...
SAN DIEGO – Certain immune-related adverse events related to PD1/PD-L1 treatment of patients with non–small cell...
WASHINGTON, D.C. – Mocetinostat/durvalumab shows activity and manageable AEs in metastatic NSCLC after progression...
MUNICH – Patients with MET exon 14–skipping mutations, but not MET gene amplification, had a high response rate to capmatinib.
News from the FDA/CDC
Prevalence dropped to 14% among adults in 2017, but control strategies need to “address the diversity of tobacco products.”
The approval was based on an overall response rate of 48% in patients previously treated with one or more ALK kinase inhibitors.
Pembrolizumab is now approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of...